FDA Approves Belzutifan for Advanced Renal Cell Carcinoma
(MedPage Today) -- The FDA approved belzutifan (Welireg) for previously treated advanced renal cell carcinoma (RCC), the agency announced on Thursday.
Belzutifan is indicated for RCC patients with disease progression after a PD-1/L1 checkpoint... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - December 15, 2023 Category: American Health Source Type: news
FDA Approves Merck ’s Welireg (belzutifan) for the Treatment of Patients With Advanced Renal Cell Carcinoma (RCC) Following a PD-1 or PD-L1 Inhibitor and a VEGF-TKI
RAHWAY, N.J.--(BUSINESS WIRE) December 14, 2023 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Welireg, an oral hypoxia-inducible factor-2... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 14, 2023 Category: Drugs & Pharmacology Source Type: news
FDA approves belzutifan for advanced renal cell carcinoma
On December 14, 2023, the Food and Drug Administration approved belzutifan (Welireg, Merck& Co., Inc.) for patients with advanced renal cell carcinoma (RCC). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 14, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Metastatic Kidney Cancer Highlights From IKCS 2023 Metastatic Kidney Cancer Highlights From IKCS 2023
Highlights on metastatic kidney cancer research from IKCS 2023 include data on zanzalintinib, a dose-finding study on belzutifan, and updates on CAR T-cell therapy, as reported by Dr Brian Rini.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 5, 2023 Category: Consumer Health News Tags: Hematology-Oncology ReCAP Source Type: news
Telix highlights first patient dosed with new renal cancer PET agent
Telix Pharmaceuticals is highlighting that the first patient has been dosed with the company's TLX250-CDx (Zr-89 DFO-girentuximab) for clear cell renal cell carcinoma, the most common and aggressive form of kidney cancer.The patient program is being conducted at Radboud University Medical Centre in Nijmegen, the Netherlands, and follows the completion of Telix's phase III ZIRCON study (Zirconium in Renal Cancer Oncology) which reported positive results, according to the firm.Telix is moving forward toward completing a Biologics License Application submission for TLX250-CDx with the U.S. Food and Drug Administration, it...
Source: AuntMinnie.com Headlines - December 4, 2023 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Subspecialties Nuclear Radiology Source Type: news
IKCS 2023: New Data in Metastatic Kidney Cancer IKCS 2023: New Data in Metastatic Kidney Cancer
Dr Katy Beckermann reviews new and encouraging data presented at IKCS 2023.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 29, 2023 Category: Consumer Health News Tags: Hematology-Oncology MDAngle Source Type: news
AI algorithm helps determine status of small renal lesions
CHICAGO -- A deep-learning AI algorithm designed to determine the malignancy status of renal lesions less than 4 cm could reduce overtreatment and undertreatment of kidney cancer, according to research presented November 26 at RSNA 2023.The AI functions by taking a preoperative CT scan as input, localizes the tumor region by segmenting it, and then predicts the probability of malignancy in a fully automated fashion, according to Aakanksha Rana, PhD, of Johnson & Johnson in New Brunswick, NJ.“The outcome was good given our small dataset,” Rana said, adding that there is much work to be done. “It’s very surprising to...
Source: AuntMinnie.com Headlines - November 26, 2023 Category: Radiology Authors: Liz Carey Tags: Resources Conference RSNA 2023 Source Type: news
Biden taps Vanderbilt physician-scientist to head NCI
It took nearly 2 years for President Joe Biden to find and the Senate to approve the new director of the U.S. National Institutes of Health (NIH), Monica Bertagnolli, who took her post last week. But Biden has moved to fill the newly vacant top job at NIH’s largest institute, the National Cancer Institute (NCI), in a tiny fraction of that time
.
Today, Biden announced that Vanderbilt University Medical Center physician-scientist Kimryn Rathmell will be NCI’s 17th director. Rathmell will replace Bertagnolli, who served just over 1 year in the position before becoming NIH director. When Rathmell takes her p...
Source: ScienceNOW - November 17, 2023 Category: Science Source Type: news
Treatment of Favorable-Risk Advanced Renal Cell Carcinoma Treatment of Favorable-Risk Advanced Renal Cell Carcinoma
Experts discuss strategies for treating patients with favorable-risk advanced renal cell carcinoma in light of IMDC guidelines and recent prospective studies.Medscape (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 17, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news
'We're Not There Yet': CAR T-Cell Therapy for Renal Cell Carcinoma
(MedPage Today) -- NASHVILLE, Tenn. -- Chimeric antigen receptor (CAR) T-cell therapy has the potential to become standard-of-care therapy for renal cell carcinoma (RCC) that does not respond to current therapies, an RCC specialist said here... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 16, 2023 Category: Hematology Source Type: news
IKCS 2023: New Advances in Metastatic Kidney Cancer IKCS 2023: New Advances in Metastatic Kidney Cancer
Dr Katy Beckermann highlights a new tyrosine kinase inhibitor and the unique collaborative discussions shaping the future of kidney cancer care, as reported at IKCS 2023.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 15, 2023 Category: Consumer Health News Tags: None MDAngle Source Type: news
Targeting New Pathways to Improve Outcomes in Renal Cell Carcinoma
(MedPage Today) -- NASHVILLE, Tenn. -- Building on the existing immune checkpoint inhibitor (ICI) platform, new treatment strategies for renal cell carcinoma (RCC) seek to adapt the cancer's immunity cycle to inform development of more effective... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 15, 2023 Category: Hematology Source Type: news
Renal Cell Carcinoma Highlights From ESMO 2023 Renal Cell Carcinoma Highlights From ESMO 2023
Dr Brian Rini reviews key studies on renal cell carcinoma from ESMO 2023, including several LITESPARK trials examining belzutifan, and the RENOTORCH trial from China looking at a IO/TKI combination.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 14, 2023 Category: Consumer Health News Tags: None ReCAP Source Type: news
No Boost in Outcomes for Clear Cell RCC With Higher Belzutifan Dose
(MedPage Today) -- NASHVILLE, Tenn. -- A higher dose of belzutifan (Welireg) being investigated for advanced clear cell renal cell carcinoma (ccRCC) did not improve outcomes as compared with the usual dose in other settings, a randomized trial... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 13, 2023 Category: Hematology Source Type: news
Tyrosine Kinase Inhibitor Active in Heavily Treated Renal Cell Carcinoma
(MedPage Today) -- NASHVILLE, Tenn. -- An investigational multitargeted drug produced objective responses in clear-cell renal cell carcinoma (ccRCC), irrespective of prior exposure to cabozantinib (Cabometyx), a small clinical trial showed.... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 12, 2023 Category: Hematology Source Type: news
